Natural Product: NPC282143
Natural Product ID:   | NPC282143 |
Common Name*:   | Methyl Alpha-D-Mannoside |
IUPAC Name:   | (2R,3S,4S,5S,6S)-2-(hydroxymethyl)-6-methoxyoxane-3,4,5-triol |
Synonyms:   | Methyl Alpha-D-Mannopyranoside; Methyl Alpha-D-Mannoside |
Standard InCHIKey:   | HOVAGTYPODGVJG-VEIUFWFVSA-N |
Standard InCHI:   | InChI=1S/C7H14O6/c1-12-7-6(11)5(10)4(9)3(2-8)13-7/h3-11H,2H2,1H3/t3-,4-,5+,6+,7+/m1/s1 |
SMILES:   | CO[C@@H]1[C@H]([C@H]([C@@H]([C@@H](CO)O1)O)O)O
|
Synthetic Gene Cluster:   |
n.a. |
ChEMBL Identifier:   |
CHEMBL195368 |
PubChem CID:   |
101798 |
Chemical Classification**:   |
-
CHEMONTID:0000000 [Organic compounds]
-
[CHEMONTID:0004603] Organic oxygen compounds
-
[CHEMONTID:0000323] Organooxygen compounds
[CHEMONTID:0000011] Carbohydrates and carbohydrate conjugates[CHEMONTID:0002105] Glycosyl compounds[CHEMONTID:0002207] O-glycosyl compounds
|
*Note: the InCHIKey will be temporarily assigned as the "Common Name" if no IUPAC name or alternative short name is available.
**Note: the Chemical Classification was calculated by NPClassifier Version 1.5. Reference: PMID:34662515.
  Species Source
Organism ID |
Organism Name |
Taxonomy Level |
Family |
SuperKingdom |
Isolation Part |
Collection Location |
Collection Time |
Reference |
NPO4414 |
Lilium lancifolium |
Species |
Liliaceae |
Eukaryota |
n.a. |
n.a. |
n.a. |
Database[TCMID] |
NPO4414 |
Lilium lancifolium |
Species |
Liliaceae |
Eukaryota |
n.a. |
n.a. |
n.a. |
Database[TCM_Taiwan] |
NPO4414 |
Lilium lancifolium |
Species |
Liliaceae |
Eukaryota |
n.a. |
n.a. |
n.a. |
Database[TM-MC] |
NPO4414 |
Lilium lancifolium |
Species |
Liliaceae |
Eukaryota |
n.a. |
n.a. |
n.a. |
Database[UNPD] |
☑ Note for Reference:
In addition to directly collecting NP source organism data from primary literature (where reference will provided as NCBI PMID or DOI links), NPASS also integrated them from below databases:
☉ UNPD: Universal Natural Products Database [PMID: 23638153].
☉ StreptomeDB: a database of streptomycetes natural products [PMID: 33051671].
☉ TM-MC: a database of medicinal materials and chemical compounds in Northeast Asian traditional medicine [PMID: 26156871].
☉ TCM@Taiwan: a Traditional Chinese Medicine database [PMID: 21253603].
☉ TCMID: a Traditional Chinese Medicine database [PMID: 29106634].
☉ TCMSP: The traditional Chinese medicine systems pharmacology database and analysis platform [PMID: 24735618].
☉ HerDing: a herb recommendation system to treat diseases using genes and chemicals [PMID: 26980517].
☉ MetaboLights: a metabolomics database [PMID: 27010336].
☉ FooDB: a database of constituents, chemistry and biology of food species [www.foodb.ca].
  NP Quantity Composition/Concentration
Organism ID |
NP ID |
Organism Material Preparation |
Organism Part |
NP Quantity (Standard) |
NP Quantity (Minimum) |
NP Quantity (Maximum) |
Quantity Unit |
Reference |
☑ Note for Reference:
In addition to directly collecting NP quantitative data from primary literature (where reference will provided as NCBI PMID or DOI links), NPASS also integrated NP quantitative records for specific NP domains (e.g., NPS from foods or herbs) from domain-specific databases. These databases include:
☉ DUKE: Dr. Duke's Phytochemical and Ethnobotanical Databases.
☉ PHENOL EXPLORER: is the first comprehensive database on polyphenol content in foods [PMID: 24103452], its homepage can be accessed at here.
☉ FooDB: a database of constituents, chemistry and biology of food species [www.foodb.ca].
  Biological Activity
Activity Type |
# Activity |
EC50 |
1 |
IC50 |
11 |
Kd |
2 |
Others |
4 |
Activity Type |
# Activity |
Individual Protein |
7 |
Organism |
1 |
Others |
7 |
SINGLE PROTEIN |
3 |
Target ID |
Target Type |
Target Name |
Target Organism |
Activity Type |
Activity Relation |
Value |
Unit |
Reference |
NPT5686 |
Individual Protein |
Concanavalin-A |
Canavalia ensiformis |
IC50 |
= |
350000.0 |
nM |
PMID[480003] |
NPT2712 |
Individual Protein |
Adhesin protein fimH |
Escherichia coli K-12 |
Ratio IC50 |
= |
29.0 |
n.a. |
PMID[480005] |
NPT2712 |
Individual Protein |
Adhesin protein fimH |
Escherichia coli K-12 |
IC50 |
= |
1900.0 |
nM |
PMID[480005] |
NPT2712 |
Individual Protein |
Adhesin protein fimH |
Escherichia coli K-12 |
IC50 |
= |
450000.0 |
nM |
PMID[480007] |
NPT2712 |
Individual Protein |
Adhesin protein fimH |
Escherichia coli K-12 |
Kd |
= |
2200.0 |
nM |
PMID[480007] |
NPT5647 |
Individual Protein |
Lectin |
Burkholderia cenocepacia (strain ATCC BAA-245 / DSM 16553 / LMG 16656/ NCTC 13227 / J2315 / CF5610) (Burkholderia cepacia (strain J2315)) |
Kd |
= |
2700.0 |
nM |
PMID[480008] |
NPT5647 |
Individual Protein |
Lectin |
Burkholderia cenocepacia (strain ATCC BAA-245 / DSM 16553 / LMG 16656/ NCTC 13227 / J2315 / CF5610) (Burkholderia cepacia (strain J2315)) |
IC50 |
= |
7000.0 |
nM |
PMID[480008] |
NPT610 |
Others |
Molecular identity unknown |
|
IC50 |
= |
1100000.0 |
nM |
PMID[480001] |
NPT3638 |
Organism |
BK polyomavirus |
BK polyomavirus |
EC50 |
> |
100000.0 |
nM |
PMID[480002] |
NPT27 |
Others |
Unspecified |
|
CC50 |
> |
100000.0 |
nM |
PMID[480002] |
NPT2 |
Others |
Unspecified |
|
IC50 |
= |
1320000.0 |
nM |
PMID[480004] |
NPT2 |
Others |
Unspecified |
|
Ratio IC50 |
= |
1.0 |
n.a. |
PMID[480004] |
NPT25502 |
SINGLE PROTEIN |
Fucose-binding lectin PA-IIL |
Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM14847 / LMG 12228 / 1C / PRS 101 / PAO1) |
IC50 |
= |
157000.0 |
nM |
PMID[480010] |
NPT25502 |
SINGLE PROTEIN |
Fucose-binding lectin PA-IIL |
Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM14847 / LMG 12228 / 1C / PRS 101 / PAO1) |
IC50 |
= |
37000.0 |
nM |
PMID[480010] |
NPT25502 |
SINGLE PROTEIN |
Fucose-binding lectin PA-IIL |
Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM14847 / LMG 12228 / 1C / PRS 101 / PAO1) |
IC50 |
= |
157000.0 |
nM |
PMID[480011] |
NPT2 |
Others |
Unspecified |
|
IC50 |
= |
101000.0 |
nM |
PMID[480012] |
NPT2 |
Others |
Unspecified |
|
IC50 |
= |
166000.0 |
nM |
PMID[480012] |
☑ Note for Activity Records:
☉ The quantitative biological activities were primarily integrated from ChEMBL (Version-30) database and were also directly collected from PubMed literature. PubMed PMID was provided as the reference link for each activity record.
  Chemically structural similarity: I. Similar Active Natural Products in NPASS
Top-200 similar NPs were calculated against the active-NP-set (includes 4,3285 NPs with experimentally-derived bioactivity available in NPASS)
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules. Tc lies between [0, 1] where '1' indicates the highest similarity. What is Tanimoto coefficient
●  The left chart: Distribution of similarity level between NPC282143 and all remaining natural products in the NPASS database.
●  The right table: Most similar natural products (Tc>=0.56 or Top200).
range |
Tanimoto Coefficient |
0-0.1 | 1188 |
0.1-0.2 | 10024 |
0.2-0.3 | 18258 |
0.3-0.4 | 9616 |
0.4-0.5 | 2918 |
0.5-0.6 | 482 |
0.6-0.7 | 99 |
0.7-0.8 | 50 |
0.8-0.85 | 17 |
0.85-0.9 | 22 |
0.9-0.95 | 12 |
0.95-1 | 11 |
  Chemically structural similarity: II. Similar Clinical/Approved Drugs
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules.
●  The left chart: Distribution of similarity level between NPC282143 and all drugs/candidates.
●  The right table: Most similar clinical/approved drugs (Tc>=0.56 or Top200).
range |
Tanimoto Coefficient |
0-0.1 | 1423 |
0.1-0.2 | 5270 |
0.2-0.3 | 1779 |
0.3-0.4 | 413 |
0.4-0.5 | 150 |
0.5-0.6 | 54 |
0.6-0.7 | 28 |
0.7-0.8 | 11 |
0.8-0.85 | 3 |
0.85-0.9 | 12 |
0.9-0.95 | 7 |
0.95-1 | 0 |
Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.9333 |
High Similarity |
NPD9000 |
Phase 3 |
0.9333 |
High Similarity |
NPD8993 |
Phase 1 |
0.9333 |
High Similarity |
NPD8998 |
Phase 2 |
0.9333 |
High Similarity |
NPD8999 |
Phase 3 |
0.9333 |
High Similarity |
NPD8997 |
Approved |
0.9167 |
High Similarity |
NPD905 |
Approved |
0.9167 |
High Similarity |
NPD904 |
Phase 3 |
0.8936 |
High Similarity |
NPD8966 |
Approved |
0.8936 |
High Similarity |
NPD8965 |
Approved |
0.88 |
High Similarity |
NPD890 |
Clinical (unspecified phase) |
0.88 |
High Similarity |
NPD894 |
Approved |
0.88 |
High Similarity |
NPD888 |
Phase 3 |
0.88 |
High Similarity |
NPD895 |
Approved |
0.88 |
High Similarity |
NPD891 |
Phase 3 |
0.88 |
High Similarity |
NPD892 |
Phase 3 |
0.88 |
High Similarity |
NPD887 |
Approved |
0.88 |
High Similarity |
NPD893 |
Approved |
0.88 |
High Similarity |
NPD889 |
Approved |
0.8667 |
High Similarity |
NPD8788 |
Approved |
0.86 |
High Similarity |
NPD2269 |
Approved |
0.8085 |
Intermediate Similarity |
NPD9006 |
Approved |
0.8077 |
Intermediate Similarity |
NPD9035 |
Clinical (unspecified phase) |
0.8077 |
Intermediate Similarity |
NPD9036 |
Phase 3 |
0.7963 |
Intermediate Similarity |
NPD2267 |
Suspended |
0.7719 |
Intermediate Similarity |
NPD6123 |
Approved |
0.7551 |
Intermediate Similarity |
NPD9218 |
Clinical (unspecified phase) |
0.7551 |
Intermediate Similarity |
NPD9219 |
Approved |
0.7458 |
Intermediate Similarity |
NPD847 |
Phase 1 |
0.74 |
Intermediate Similarity |
NPD8994 |
Approved |
0.7273 |
Intermediate Similarity |
NPD7346 |
Approved |
0.7193 |
Intermediate Similarity |
NPD369 |
Approved |
0.7143 |
Intermediate Similarity |
NPD8957 |
Approved |
0.7143 |
Intermediate Similarity |
NPD8958 |
Phase 2 |
0.7111 |
Intermediate Similarity |
NPD9053 |
Approved |
0.7111 |
Intermediate Similarity |
NPD9052 |
Approved |
0.7111 |
Intermediate Similarity |
NPD9051 |
Approved |
0.7049 |
Intermediate Similarity |
NPD1457 |
Discontinued |
0.6984 |
Remote Similarity |
NPD897 |
Approved |
0.6984 |
Remote Similarity |
NPD896 |
Approved |
0.6984 |
Remote Similarity |
NPD898 |
Approved |
0.6909 |
Remote Similarity |
NPD9050 |
Approved |
0.6909 |
Remote Similarity |
NPD9049 |
Discontinued |
0.6885 |
Remote Similarity |
NPD8961 |
Approved |
0.6735 |
Remote Similarity |
NPD8995 |
Clinical (unspecified phase) |
0.6735 |
Remote Similarity |
NPD8996 |
Phase 3 |
0.66 |
Remote Similarity |
NPD8967 |
Approved |
0.6562 |
Remote Similarity |
NPD9031 |
Approved |
0.6562 |
Remote Similarity |
NPD9030 |
Approved |
0.6562 |
Remote Similarity |
NPD9033 |
Approved |
0.6562 |
Remote Similarity |
NPD9032 |
Approved |
0.6552 |
Remote Similarity |
NPD885 |
Approved |
0.6552 |
Remote Similarity |
NPD884 |
Clinical (unspecified phase) |
0.6515 |
Remote Similarity |
NPD9445 |
Approved |
0.6481 |
Remote Similarity |
NPD9139 |
Approved |
0.6471 |
Remote Similarity |
NPD3181 |
Approved |
0.6444 |
Remote Similarity |
NPD8814 |
Phase 3 |
0.6333 |
Remote Similarity |
NPD8959 |
Approved |
0.6176 |
Remote Similarity |
NPD7532 |
Clinical (unspecified phase) |
0.6164 |
Remote Similarity |
NPD7329 |
Approved |
0.614 |
Remote Similarity |
NPD1400 |
Approved |
0.614 |
Remote Similarity |
NPD1399 |
Approved |
0.6 |
Remote Similarity |
NPD389 |
Phase 3 |
0.6 |
Remote Similarity |
NPD9034 |
Approved |
0.6 |
Remote Similarity |
NPD67 |
Phase 2 |
0.5915 |
Remote Similarity |
NPD1811 |
Approved |
0.5915 |
Remote Similarity |
NPD1810 |
Approved |
0.589 |
Remote Similarity |
NPD9434 |
Approved |
0.589 |
Remote Similarity |
NPD9435 |
Approved |
0.5789 |
Remote Similarity |
NPD9061 |
Clinical (unspecified phase) |
0.5778 |
Remote Similarity |
NPD8549 |
Clinical (unspecified phase) |
0.5769 |
Remote Similarity |
NPD361 |
Discontinued |
0.5753 |
Remote Similarity |
NPD372 |
Clinical (unspecified phase) |
0.5686 |
Remote Similarity |
NPD8976 |
Approved |
0.5686 |
Remote Similarity |
NPD8977 |
Phase 3 |
0.5614 |
Remote Similarity |
NPD9005 |
Phase 3 |
0.5614 |
Remote Similarity |
NPD9003 |
Clinical (unspecified phase) |
0.5614 |
Remote Similarity |
NPD9004 |
Approved |
0.56
|
Remote Similarity |
NPD370 |
Phase 3 |